Steed
Member
- Joined
- Jun 30, 2020
- Messages
- 89
... After disappointing last phase trials last year of the antibody drug against beta amyloid plaque called Aducanumab. FDA is now only 1 year later about to approve the drug because of substantial evidence the drug works from one successful lasts phase study. There has been no further trials but FDA overrides the clinical data from one of the failed clinical trials.
Biogen scraps two Alzheimer drug trials, wipes $18 billion from market value
Biogen shares leap after ‘substantial evidence’ Alzheimer’s drug is effective
Biogen scraps two Alzheimer drug trials, wipes $18 billion from market value
Biogen shares leap after ‘substantial evidence’ Alzheimer’s drug is effective
Last edited:
